Low testosterone levels predict an increased likelihood of high-grade prostate cancer being found as a result of a prostate biopsy, new findings suggest.
A team led by Hyeon Jeong, MD, of Seoul Metropolitan Government Seoul National University, retrospectively studied 681 men who underwent an initial 12-core transrectal prostate biopsy. Of these, 86 had low testosterone levels (less than 300 ng/dL) and 143 had normal levels (300 ng/dL or higher). In addition, 143 men had a positive biopsy and 99 had high-grade prostate cancer.
In multivariable analysis, compared with a normal testosterone level, a low testosterone level was not significantly associated with a prostate cancer diagnosis overall, but it was associated with a significant 2.1 times increased risk for high-grade prostate cancer, the investigators reported online ahead of print in BJU International.
“Low testosterone level is an independent risk factor for high-grade prostate cancer detection at biopsy,” the researchers concluded. “Therefore, checking testosterone levels could help to determine whether prostate biopsy should be carried out.”
This article originally appeared on Renal and Urology News